drugset / Trial / NCT02479802

Efficacy and Safety of Plasma Exchange With Albumin in Patients With Amyotrophic Lateral Sclerosis

NCT02479802

Phase 2 Completed 13 enrolled Grifols, S.A.
NaSingle-groupOpen-labelTreatment

Summary

Pilot, phase II, prospective, open-label, uncontrolled study of plasma exchange with 5% albumin in 10 subjects having a definite, possible, or probable diagnosis of Amyotrophic Lateral Sclerosis (ALS).

Timeline

Start
2014-11
Primary completion
2016-06
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Albumin Protein / enzyme biologic 5 %
Subject Albumin Protein / enzyme biologic 3000 ml